Fepixnebart clinical trials
Also written LY3016859.
How each study uses fepixnebart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fepixnebart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY3016859
- 4
Studies by the year they started
6 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2020 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
LY3556050 (1) · LY-3526318 (1) · LY3857210 (1) · LY4065967 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test fepixnebart.
- Apr 2027A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainPhase 2 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses fepixnebart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainRecruitingPhase 2Eli Lilly and CompanyNCT05986292Written as LY3016859 ISA
- Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back PainCompletedPhase 2Eli Lilly and CompanyNCT04529096Written as LY3016859
- Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With OsteoarthritisCompletedPhase 2Eli Lilly and CompanyNCT04456686Written as LY3016859
- Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic PainCompletedPhase 2Eli Lilly and CompanyNCT04476108Written as LY3016859
- Study of LY3016859 in Participants With Diabetic NephropathyCompletedPhase 1/2Eli Lilly and CompanyNCT01774981Written as LY3016859
- A Study of LY3016859 in Healthy VolunteersCompletedPhase 1Eli Lilly and CompanyNCT01545583Written as LY3016859 intravenous
Codes
What other systems call fepixnebart · ClinicalTrials.gg INT016581
- UNII (FDA) FP2PL0HRK8FEPIXNEBARTOne source FDA
- NCI Thesaurus C188574FepixnebartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FP2PL0HRK8 | FEPIXNEBART | One source FDA |
| NCI Thesaurus | C188574 | Fepixnebart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.